Clinical Trial Update: Low-dose Temozolomide for 2 Weeks on Brain Tumor Enzyme in Patients With Gliomas (P04602 AM1) (Completed) [Phase 2]

View source ↗

Summary

This update reports the completion of a Phase 2 trial evaluating low-dose temozolomide given for two weeks in patients with glioma; results were posted in 2011.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Glioma

Drugs mentioned

• Temozolomide (Temozolomide)

Snippet

Sponsor: Merck Sharp & Dohme LLC | Conditions: Glioma | Phase 2 | Status: COMPLETED | Results posted: 2011-06-29